阿斯利康,在CGT赛道狂奔

新康界
19 Mar

来源:同写意阿斯利康虽然一直是抗肿瘤领域的主要参与者,但在过去几年中,它明显缺席了第一波商业化CAR-T疗法的盛宴。不过,交易正在帮助这家巨头缩小差距。3月17日,阿斯利康宣布收购EsoBiotec,布局体内CAR-T等细胞疗法。按照公告,阿斯利康将支付4.25亿美元预付款,以及5.75亿美元基于开发和监管的里程碑金额——交易总额最高可达10亿美元。01改变CAR-T游戏规则?EsoBiotec...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10